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Abstract It has been shown that a decreased vesicular
monoamine transporter (VMAT2) function and the dis-
ruption of dopamine (DA) storage is an early contributor to
oxidative damage of dopamine neurons in Parkinson’s
disease (PD). In our previous study, we demonstrated that
adenosine A2A receptor antagonists suppressed oxidative
stress in 6-hydroxydopamine-treated rats suggesting that
this effect may account for neuroprotective properties of
drugs. In the present study, rats were injected with reser-
pine (10 mg/kg sc) and 18 h later the effect of the adeno-
sine A2A receptor antagonists 8-(3-chlorostyryl)caffeine
(CSC) and 4-(2-[7-amino-2-(2-furyl)[1,2,4]triazolo[2,3-a]
[1,3,5]triazin-5-ylamino]ethyl)phenol (ZM 241385) on
extracellular DA, glutamate and hydroxyl radical formation
was studied in the rat striatum using in vivo microdialysis.
By disrupting VMAT2 function, reserpine depleted DA
stores, and increased glutamate and hydroxyl radical levels
in the rat striatum. CSC (1 mg/kg) but not ZM 241385
(3 mg/kg) increased extracellular DA level and production
of hydroxyl radical in reserpinised rats. Both antagonists
decreased the reserpine-induced increase in extracellu-
lar glutamate. L-3,4-Dihydroxyphenylalanine (L-DOPA)
(25 mg/kg) significantly enhanced extracellular DA, had
no effect on reserpine-induced hydroxyl radical production
and decreased extracellular glutamate concentration. CSC
but not ZM 241385 given jointly with L-DOPA increased
the effect of L-DOPA on extracellular DA and augmented
the reserpine-induced hydroxyl radical production. CSC
and ZM 241385 did not influence extracellular glutamate
level, which was decreased by L-DOPA. It seems that by
decreasing the MAO-dependent DA metabolism rate, CSC
raised cytosolic DA and by DA autoxidation, it induced
hydroxyl radical overproduction. Thus, the methylxanthine
A2A receptor antagonists bearing properties of MAO-B
inhibitor, like CSC, may cause a risk of oxidative stress
resulting from dysfunctional DA storage mechanism in
early PD.
Keywords Parkinson’s disease  Adenosine A2A receptor
antagonists  VMAT2 function  Oxidative stress
Introduction
Progressive degeneration of the dopamine-containing
neurons in the substantia nigra pars compacta results in
deficiency of striatal dopamine (DA) and loss of neuro-
chemical transport systems, such as the dopamine trans-
porter (DAT) and the vesicular monoamine transporter
(VMAT2) (Miller et al. 1997, 1999). PET studies in a non-
human primate model of Parkinson’s disease (PD) showed
that a decreased VMAT2 function and the disruption of DA
sequestration was an early and potent contributor to oxi-
dative damage of dopamine neurons in PD pathogenesis
(Chen et al. 2008).
DA is a highly reactive molecule that is capable of
autoxidation to a quinone in the basic pH of the cytosol.
Furthermore, cytosolic MAO-dependent DA metabolism
leads to the formation of aldehydes and peroxides (Halliwell
2006). Regarding the role of oxidative stress in the patho-
genesis of PD, packing of cytosolic DA into synaptic vesi-
cles by VMAT2 prevents its autoxidation and subsequent
degeneration of dopamine neurons. An animal model of PD
mimicking the altered DA homeostasis by impaired DA
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storage mechanisms is based on the administration of the
irreversible VMAT2 inhibitor reserpine to rats (Carlsson
et al. 1957). Reserpine reduces vesicular storage and release
of brain monoamines and leads to the accumulation of oxi-
dative products of neurotransmitters (Caudle et al. 2007).
Recently, antagonists of adenosine A2A receptors
appeared as a new promising non-dopaminergic therapy of
PD. Striatopallidal neurons are highly enriched in adeno-
sine A2A receptors which occur there as heteromeric
complexes with dopamine D2 receptors (Ferre´ et al. 1993).
Behavioral studies in rodents and in non-human primates
showed that A2A receptor antagonists reversed motor
impairment induced by 6-hydroxydopamine (6-OHDA) or
MPTP (Schwarzschild et al. 2006; Morelli et al. 2007). The
mechanism of antiparkinsonian effects of A2A receptor
antagonists is based on their ability to modulate GABA
release and DA-dependent c-fos activation in the indirect
striatopallidal pathway (Pollack and Fink 1995; Ochi et al.
2000). In addition, presynaptic A2A receptors are able to
control corticostriatal glutamatergic transmission by
counteracting D2 receptor function (Tozzi et al. 2007).
Several epidemiological and animal studies have suggested
neuroprotective effects of caffeine and selective A2A
adenosine receptor antagonists (Ross et al. 2000; Ascherio
et al. 2001; Xu et al. 2005; Chen et al. 2007). A protective
effect of caffeine and more selective antagonists of A2A
receptors, similar to genetic inactivation of A2A receptors,
was observed in an animal MPTP neurotoxicity model (Xu
et al. 2005; Chen et al. 2007) or in ischemia and excitotoxic
brain injury models (Popoli et al. 2004; Chen et al. 2007).
The mechanism allowing A2A receptor antagonists to
protect dopaminergic neurons has not been fully explained
yet, but a variety of their effects on various types of neu-
rons, e.g., glutamatergic nerve terminals and glial or
immune cells, suggest its complex nature (Chen et al.
2007). In our earlier study, we have shown that A2A
receptor antagonists decreased the production of free rad-
ical and lowered extracellular glutamate level in 6-OHDA-
treated rats (Gołembiowska et al. 2009; Gołembiowska and
Dziubina 2012). Moreover, A2A receptor antagonists
administered in combination with L-3,4-Dihydroxyphenyl-
alanine (L-DOPA) did not change inhibitory effect of
L-DOPA on free radical generation and glutamate
enhancement in the striatum of 6-OHDA-treated rats
(Gołembiowska and Dziubina 2012).
A class of A2A antagonists belonging to methylxanthine
derivatives offers a neuroprotective benefit as MAO-B
inhibitors (Castagnoli et al. 2003). Inhibition of DA deg-
radation by MAO-B attenuates hydrogen peroxide forma-
tion, but at the same time it increases the risk of DA
autoxidation resulting from augmentation of the cytosolic
DA pool. Therefore, in our present study, we aimed to
investigate whether two A2A receptor antagonists 8-(3-
chlorostyryl)caffeine (CSC) and 4-(2-[7-amino-2-(2-
furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)
phenol (ZM 241385) belonging to different chemical
classes (methylxanthine and non-xanthine derivatives,
respectively) can modulate extracellular level of DA and
glutamate as cellular sources of hydroxyl radical in animals
with reduced VMAT2 function after reserpine administra-
tion. Since L-DOPA may be toxic in the brain by pro-
moting the formation of reactive species and neurotoxic
quinones when cytosolic level of DA increases after dis-
ruption of DA storage mechanisms (Halliwell 2006), we
also studied the effect of A2A receptor antagonists given in
combination with L-DOPA in rats treated with reserpine.
Materials and Methods
Animals
Microdialysis studies were conducted in male Wistar rats
(250–300 g), bred at the Institute of Pharmacology, Polish
Academy of Sciences, Krakow, Poland. The rats were
housed in temperature- and humidity-controlled rooms on a
12-h light/dark cycle, with free access to filtered tap water
and standard pelleted laboratory chow throughout the
study. The experimental procedures and housing conditions
used were in strict accordance with the Polish legal regu-
lations concerning experiments on animals (Dz. U.
05.33.289). All the experimental protocols were approved
by the Local Bioethics Commission for Animal
Experiments.
Drugs
L-DOPA, CSC, benserazide, and p-hydroxybenzoic acid
(PBA) were obtained from Sigma-Aldrich (Poznan´, Poland),
reserpine was obtained from Fluka-Analytical, Poland),
whereas 4-(2-[7-amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]
triazin-5-ylamino]ethyl)phenol (ZM 241385) came from
TOCRIS (Warsaw, Poland). All the chemicals used for
HPLC were purchased from Merck (Warsaw, Poland).
L-DOPA and benserazide were dissolved in saline. A solu-
tion of PBA was prepared in an artificial cerebrospinal fluid
(aCSF) and was then adjusted to pH 7.4 with 0.1 M NaOH.
CSC was initially dissolved in dimethyl sulfoxide (DMSO;
Sigma-Aldrich, Poznan´, Poland) and was then diluted in at
least 20 vols. of the vehicle consisting of a 20:80 (v/v)
mixture of Alkamulus EL-620 (Rhone-Poulenc, Cranbury,
NJ) and a phosphate-buffered saline. ZM 241385 was dis-
solved in a small amount of DMSO and then was diluted in
Cremophor EL (Sigma-Aldrich, Poznan´, Poland) and 0.9%
NaCl (final concentration: a 15% DMSO and a 15% Crem-
ophor EL). All injections were made by an intraperitoneal
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route (i.p.). Reserpine dissolved in a mixture of benzyl
alcohol (2 ml), citric acid (250 mg), and Tween-80 in H2O
was given in a dose of 10 mg/kg 18 h before microdialysis
experiment. CSC (1 mg/kg) and ZM 241385 (3 mg/kg) were
given in single injections as indicated in the figures. L-DOPA
(25 mg/kg) was injected 20 min after the administration
of A2A receptor antagonists together with benserazide
(12.5 mg/kg). Control animals received respective vehicles.
Determination of Monoamine Levels
For the measurement of dopamine (DA), 3,4-dihydroxy-
phenylacetic acid (DOPAC) and homovanilic acid (HVA),
the brain tissue was homogenized in 0.1 M HClO4, cen-
trifuged at 4C for 5 min at 10,0009g, and the supernatant
was filtered through 0.1 lm (Millipore) membranes. An
aliquot of 2–5 ll of each sample was then injected into a
high performance liquid chromatograph (HPLC) with
electrochemical detection.
In Vivo Microdialysis
The rats were anaesthetized with ketamine (75 mg/kg i.m.)
and xylazine (10 mg/kg i.m.) and placed in a stereotaxic
apparatus (David Kopf Instruments, Tujunga, CA, USA).
Their skulls were exposed and small holes were drilled for
the insertion of microdialysis probes into the striatum using
the following coordinates: 1.8 mm anterior from the
bregma; 2.8 mm lateral from the sagittal suture; -7.0 mm
ventral from the dura (Paxinos and Watson 1998). Vertical
microdialysis probes were constructed as described in
detail elsewhere (Gołembiowska et al. 2009). Probe inlets
were connected to a syringe pump (BAS, IN, USA) which
delivered an aCSF composed of [mM]: NaCl 147, KCl 4.0,
MgCl2 1.0, CaCl2 2.2; pH 7.4 at a flow rate of 2 ll/min. All
metal parts of the aCSF delivery system were replaced with
PEEK components or were passivated with 6 M HNO3.
Baseline samples were collected every 20 min after the
washout period to obtain a stable extracellular neuro-
transmitter level. Appropriate drugs were then adminis-
tered 20 min before L-DOPA injection given at time 0, as
shown in figures, and dialysate fractions were collected for
240 min. At the end of the experiment, the rats were killed
and their brains were histologically examined to validate
probe placement.
Analytical Procedure
DA, DOPAC, and HVA were analyzed by HPLC with an
electrochemical detection. The level of hydroxyl radicals
was estimated as 3,4-dihydroxybenzoic acid (3,4-DHBA),
a product of the spin trap reagent PBA (1 mM) applied via
the microdialysis probe. DA and its metabolites were
simultaneously determined in the same fractions of striatal
dialysates. Chromatography was performed using an LC-
10 AD pump (Shimadzu Europa GmbH, Warsaw, Poland),
an LC-4B amperometric detector with a cross-flow detector
cell (BAS, IN, USA) and a BDS-Hypersil C18 analytical
column (3 9 100 mm, 3 lm; Thermo Electron Corp.,
UK). The mobile phase consisted of 0.1 M monochloro-
acetic acid adjusted to pH 3.7 with 3 M sodium hydroxide,
0.5 mM EDTA, 13 mg/l 1-octanesulfonic acid sodium salt,
a 5.7% methanol, and a 0.8% acetonitrile. The flow rate
was 0.5 ml/min, and the applied potential of a 3-mm glassy
carbon electrode was ?600 mV at a sensitivity of 2 nA/V.
Concentrations of all compounds were calculated by
comparing their peak areas with respective standards and
were processed by Chromax 2001 (Pol-Lab, Warsaw,
Poland) software run on a personal computer. The obtained
values were not corrected for in vitro probe recovery,
which was approximately 10–15%.
Glutamate was measured in dialysates (20 ll) after
derivatization with 4-dimethylaminoazobenzene-40-sulfo-
nylchloride (DABS-Cl) at 70C for 12 min, according to
Knecht and Chang (1986). Dabsylated amino acids were
separated on an Ultrasphere ODS (4.6 9 150 mm, 3 lm)
column (Supelco, Poznan´, Poland) by gradient elution,
with solvent A (10 mM citric acid, 4% dimethylformam-
ide) and solvent B (acetonitrile). Dabsylated compounds
were detected by measuring an absorbance at 436 nm using
Beckman Amino Acid System Gold with VIS detection.
Data Analysis
All obtained data are given in absolute numbers. The
statistical significance of differences between experimen-
tal groups was calculated using a one-way ANOVA for
repeated-measures, followed by Tukey’s post hoc test.
The results were considered statistically significant at
P \ 0.05.
Results
The Effects of Reserpine on DA, DOPAC, HVA
in the Rat Striatum
Reserpine produced a substantial depletion of DA and
changed the level of its metabolites DOPAC and HVA 24 h
after the injection (Table 1). Dialysate level of DA was
decreased by ca. 96%, while DOPAC and HVA extracel-
lular concentrations were increased by 44 and 11% of
control, respectively. The content of striatal DA was
attenuated by ca. 95%, while DOPAC and HVA contents
152 Neurotox Res (2012) 22:150–157
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were increased by 33 and 58%, respectively. These results
indicate reserpine-induced damage of intracellular DA
stores and increase in DA turnover.
The Effects of CSC and ZM 241385 on Extracellular
Level of DA, Glutamate and Production of Hydroxyl
Radical in Reserpine-Treated Rats
CSC (1 mg/kg) increased, while ZM 241385 (3 mg/kg) did
not influence extracellular level of DA in the rat striatum
attenuated by reserpine (Fig. 1a). Repeated- measures
ANOVA showed a significant effect of treatment
(F3,15 = 37.63, P = 0), but a non-significant effect of time
(F14,210 = 1.53, P = 0.103), and no interaction between
both factors (F42,210 = 1.099, P = 0.33). Post hoc analysis
with Tukey’s test showed that CSC significantly increased
extracellular DA level from 20 to 200 min (P \ 0.05–0.01
in comparison with reserpine).
Hydroxyl radical production was increased in the stria-
tum of reserpinized rats (Fig. 1b). CSC (1 mg/kg), but not
ZM 241385 (3 mg/kg), further increased its production
(Fig. 1b). Repeated-measures ANOVA showed a signifi-
cant effect of treatment (F3,18 = 24.21, P = 0.00001),
time (F11,198 = 22.56, P = 0), and an interaction between
both factors (F33,198 = 5.27, P = 0). Post hoc analysis
with Tukey’s test showed that CSC significantly increased
production of hydroxyl radical from 20 to 240 min after
the administration (P \ 0.05–0.01 in comparison with
reserpine).
Extracellular glutamate level was increased by reserpine
in comparison with control group (Fig. 1c). CSC (1 mg/kg)
and ZM 241385 (3 mg/kg) decreased the reserpine-
enhanced extracellular glutamate level, to control values
(Fig. 1c). Repeated-measures ANOVA showed a signifi-
cant effect of treatment (F3,12 = 6.79, P = 0.006), time
(F14,168 = 4.46, P = 0.00001) and an interaction between
both factors (F42,168 = 1.97, P = 0.001). Post hoc analysis
with Tukey’s test showed that CSC and ZM 241385 sig-
nificantly decreased extracellular glutamate level from 40
Table 1 Tissue content and
dialysate level of DA, DOPAC,
and HVA in the striatum of
control and reserpine
(10 mg/kg)-treated rats
* P \ 0.01 versus control
Mean ± SEM (n)
DA (pg/10 ll) DOPAC (ng/10 ll) HVA (ng/10 ll)
Dialysate
Control 10.5 ± 0.53 (43) 2.8 ± 0.11 (39) 1.9 ± 0.05 (39)
Reserpine 0.4 ± 0.06 (44)* 4.0 ± 0.07 (36)* 2.11 ± 0.06 (39)*
% of control 3.9 144 111
DA (ng/mg wt) DOPAC (ng/mg wt) HVA (ng/mg wt)
Tissue
Control 12,442 ± 956 (12) 1,331 ± 76 (12) 870 ± 118 (12)
Reserpine 568 ± 99 (12)* 1,773 ± 327 (12)* 1,378 ± 281 (12)*
% of control 5 133 158
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Fig. 1 The effects of CSC (1 mg/kg) and ZM 241385 (3 mg/kg) on
extracellular concentrations of DA (a), hydroxyl radical (3,4-DHBA,
b) and glutamate (GLU, c) in the striatum of rats treated with
reserpine (10 mg/kg). The injection of drugs is indicated by an arrow.
The data are the mean ± SEM (n = 5–7). *P \ 0.05; **P \ 0.01
versus control; ^P \ 0.05; ^^P \ 0.01 versus reserpine
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to 240 min after administration (P \ 0.01 in comparison
with reserpine).
The Effect of L-DOPA on Extracellular Level of DA,
DOPAC, HVA, Glutamate and Production of Hydroxyl
Radical in Reserpine-Treated Rats
L-DOPA (25 mg/kg) increased the level of DA, DOPAC,
and HVA in the striatum of reserpinized rats (Figs. 2a, 3a,
b). Repeated-measures ANOVA showed a significant effect
of treatment on DA (F2,11 = 30.55, P = 0.00003), time
(F14,154 = 2.34, P = 0.006), but no interaction for both
factors (F28,154 = 1.49, P = 0.07). Post hoc analysis with
Tukey’s test showed that L-DOPA significantly increased
extracellular DA concentration (P \ 0.05–0.01) in com-
parison with reserpine. Repeated- measures ANOVA
showed a significant effect of treatment on DOPAC
(F2,14 = 20.66, P = 0.0001), time (F14,196 = 19.75,
P = 0) and interaction for both factors (F28,196 = 18.85,
P = 0). Post hoc analysis with Tukey’s test showed that
L-DOPA significantly increased extracellular DOPAC
(P \ 0.01) in comparison with reserpine. Repeated-mea-
sures ANOVA showed a significant effect of treatment on
HVA (F2,14 = 18.71, P = 0.0001), time (F14,196 = 12.9,
P = 0), and interaction for both factors (F28,196 = 18.43,
P = 0). Post hoc analysis with Tukey’s test showed that
L-DOPA significantly increased extracellular HVA
(P \ 0.01) in comparison with reserpine.
Hydroxyl radical production, increased by reserpine,
was not changed in rats treated with L-DOPA (Fig. 2b).
Repeated-measures ANOVA showed a significant effect of
treatment (F2,13 = 4.47, P = 0.03), time (F11,143 = 19.55,
P = 0) and an interaction between both factors
(F22,143 = 1.71, P = 0.03). Post hoc analysis with Tukey’s
test showed a significant difference (P \ 0.01) between
control and reserpine or control and a combination of
reserpine and L-DOPA (Fig. 2b).
Extracellular glutamate concentration, increased by
reserpine, was decreased by L-DOPA to the control level
(Fig. 2c). Repeated-measures ANOVA showed a signifi-
cant effect of treatment (F2,10 = 7.52, P = 0.01), there
was no significant effect of time (F14,140 = 1.27,
P = 0.23) and there was an interaction between both fac-
tors (F28,140 = 1.73, P = 0.02). Post hoc analysis with
Tukey’s test showed a significant effect of L-DOPA on
extracellular glutamate level (P \ 0.01).
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Fig. 2 The effect of L-DOPA (25 mg/kg) on extracellular concen-
trations of DA (a), hydroxyl radical (3,4-DHBA, b) and glutamate
(GLU, c) in the striatum of rats treated with reserpine (10 mg/kg).
The injection of L-DOPA is indicated by an arrow. The data are the
mean ± SEM (n = 5–7). ** \ 0.0P1 versus control; ^P \ 0.05;
^^P \ 0.01 versus reserpine
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Fig. 3 The effect of L-DOPA (25 mg/kg) on extracellular concen-
trations of DOPAC (a), and HVA (b) in the striatum of rats treated
with reserpine (10 mg/kg). The injection of L-DOPA is indicated by
an arrow. The data are the mean ± SEM (n = 5–7). *P \ 0.05;
**P \ 0.01 versus control; ^^P \ 0.01 versus reserpine
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The Effects of CSC and ZM 241385 Administered Together
with L-DOPA on Extracellular Level of DA, Glutamate
and Production of Hydroxyl Radical in Reserpine-Treated
Rats
CSC (1 mg/kg), but not ZM 241385 (3 mg/kg) enhanced
extracellular DA level, increased by L-DOPA (25 mg/kg)
(Fig. 4a). Repeated-measures ANOVA showed a signifi-
cant effect of treatment (F3,16 = 4.04, P = 0.03), time
(F14,224 = 7.73, P = 0), and an interaction between both
factors (F42,224 = 2.89, P = 0). Post hoc analysis with
Tukey’s test showed a significant effect of L-DOPA
(P \ 0.05–0.01) in comparison with the reserpine group
and a significant effect of CSC (P \ 0.05–0.01) in
comparison with rats treated with reserpine and L-DOPA.
The L-DOPA-increased extracellular levels of DOPAC and
HVA were unchanged by CSC and ZM 241385 (results not
shown).
Production of hydroxyl radical was markedly increased
by CSC (1 mg/kg) given to rats treated with reserpine and
L-DOPA, but there was no effect of ZM 241385 (Fig. 4b).
Repeated-measures ANOVA showed a significant effect of
treatment (F4,22 = 15.69, P = 0.00001), time (F11,242 =
11.34, P = 0), and there was an interaction between both
factors (F44,242 = 2.86, P = 0). Post hoc analysis with
Tukey’s test showed significant effect of CSC (P \
0.05–0.01).
Extracellular glutamate was decreased by L-DOPA,
CSC (1 mg/kg), and ZM 241385 (3 mg/kg) to control level
(Fig. 4c). Repeated-measures ANOVA showed a signifi-
cant effect of treatment (F4,20 = 11.46, P = 0.00005),
time (F14,280 = 15.38, P = 0), and interaction between
both factors (F56,280 = 3.34, P = 0). Post hoc analysis
with Tukey’s test showed a significant effect of CSC, ZM
241385, and L-DOPA (P \ 0.01) in comparison with
reserpine.
Discussion
Numerous animal studies and clinical trials have demon-
strated that A2A receptor antagonists are able to improve
motor deficits in advanced PD (Xu et al. 2005; Jenner et al.
2009). Later, experimental and epidemiologic evidence
suggested neuroprotective potential for A2A receptor
antagonists (Chen et al. 2007; Jenner et al. 2009). Thus,
these drugs used early in the therapy of PD might slow or
halt degeneration of dopaminergic neurons. The neuro-
protective mechanism of A2A antagonists is not fully
understood, but our former study showed that A2A antag-
onists decreased free radical production and indicated that
overactive glutamate neurotransmission might be the
source of oxidative stress in the animal model of PD in
which nigrostriatal neurons were damaged with 6-OHDA
(Gołembiowska and Dziubina 2012). The data of the
present study show that reserpine, by irreversibly blocking
VMAT2, caused DA depletion in the rat striatum by ca.
95% in extraneuronal space as well as in intraneuronal DA
pool. In contrast to the decrease in DA, the level of
extraneuronal and intraneuronal DOPAC and HVA was
increased, indicating on accelerated turnover in existing
dopamine neurons. An increased MAO-catalyzed DA
metabolism yields hydrogen peroxide for Fenton reaction
while DA in slightly basic pH of the cytosol undergoes
autoxidation into quinones (Asanuma et al. 2003). The
inhibition of VMAT2 is similar to the beginning of PD as
shown by Chen et al. (2008), who reported that MPTP
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Fig. 4 The effects of CSC (1 mg/kg) and ZM 241385 (3 mg/kg) on
L-DOPA (25 mg/kg)-induced change in extracellular level of DA (a),
hydroxyl radical (3,4-DHBA, b), and glutamate (GLU, c) in the
striatum of rats treated with reserpine (10 mg/kg). The injection of
drugs is indicated by an arrow. The data are the mean ± SEM
(n = 5–7). *P \ 0.05; **P \ 0.01 versus control; ^P \ 0.05;
^^P \ 0.01 versus reserpine; ?P \ 0.05; ??P \ 0.01 versus reser-
pine ? L-DOPA
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administration into non-human primates induced a
decrease in the striatal VMAT2 which preceded nigrostri-
atal dopamine neuron degeneration. Our data indicate that
dysfunction of DA storage induced by reserpine promotes
the formation of DA-oxidative products and leads to
generation of free radicals. Furthermore, the decrease in
synaptic DA and the lack of inhibitory control of presyn-
aptic D2 receptors on cortico-striatal terminals (Donzanti
et al. 1993) results in augmentation of glutamate release.
Excitotoxicity due to overactive glutamate neurotransmis-
sion is able to accelerate extracellular free radical forma-
tion (Morari et al. 1998).Thus, dysfunction of DA storage
and overactive glutamate neurotransmission caused by
reserpine may induce an increase in free radical produc-
tion. Both A2A receptor antagonists, CSC and ZM 241385
used in our study in reserpine-treated rats by the blockade
of adenosine A2A receptor normalized glutamate neuro-
transmission in cortico-striatal terminals. However, CSC
and ZM 241385 differed in their effect on the striatal DA,
since CSC, but not ZM 241385 increased DA release in the
striatum of reserpine-treated rats. As mentioned in the
introduction, CSC is not only A2A receptor antagonist, but
also effectively inhibits MAO-B activity. This later CSC
capacity may increase the cytosolic DA and by its autox-
idation may lead to the increased hydroxyl radical forma-
tion, especially in rats with dysfunctional VMAT2. ZM
241385, devoid of the effect on MAO-B activity, did not
influence DA concentration and hydroxyl radical forma-
tion. The restoration of glutamate neurotransmission by
CSC and ZM 241385 does not seem to influence generation
of hydroxyl radical in reserpine-treated rats—these results
are different in comparison with our earlier study, where in
the absence of dopamine innervation, the increased gluta-
mate seemed to be responsible for free radical production
(Gołembiowska and Dziubina 2012).
L-DOPA in a single dose of 25 mg/kg effectively
increased extracellular DA level, inhibited reserpine-
induced increase in extracellular glutamate, but did not
influence hydroxyl radical formation. Normalization of
glutamate release seems to be mediated via D2 receptor
stimulated by L-DOPA-derived DA, as shown also by
others (Meshul et al. 2000; Jonkers et al. 2002). However,
the lack of L-DOPA effect on the increased hydroxyl
radical production by reserpine indicates that glutamate
does not seem to be an essential source of free radicals in
this acute animal model of PD. It suggests that the accel-
erated DA metabolism in dopaminergic neurons observed
in rats with dysfunctional VMAT2 and a marked increase
of DOPAC and HVA extracellular concentration may
account for the high level of hydroxyl radical in spite of
L-DOPA normalized glutamate release. This is in opposi-
tion to our earlier study where an enhanced glutamate and
hydroxyl radical formation in 6-OHDA-treated rats were
both decreased by L-DOPA administration (Gołembiowska
and Dziubina 2012).
In the present study, CSC enhanced L-DOPA-induced
increase in extracellular DA and markedly augmented
hydroxyl radical production, while ZM 241385 was without
effect on either DA or hydroxyl radical level. It seems that
CSC by decreasing the MAO-catalyzed DA metabolic rate
under conditions of augmented DA synthesis by exogenous
L-DOPA raises cytosolic DA pool, and induces its autoxi-
dation and hydroxyl radical overproduction. The increase in
hydroxyl radical formation by combination of CSC and
L-DOPA was not observed in normal rats (Gołembiowska
et al. 2009). Thus, functional storage mechanism is an
important factor in proper DA utilization and does not allow
for the formation of DA-oxidative products even though
neurons are overloaded with exogenous L-DOPA.
The findings of our study indicate that the inhibition of
glutamate neurotransmission by A2A receptor antagonists
showed also in other studies (reviewed by Popoli et al.
2004) might account for relief of motor symptoms and
neuroprotection observed in the models of late-stage PD
(reviewed by Chen et al. 2007; Gołembiowska and Dziu-
bina 2012). However, methylxanthine derivatives, such as
CSC, bearing properties of MAO-B inhibition may cause a
risk of oxidative stress resulting from dysfunctional
VMAT2 and DA storage mechanism in an early PD.
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